These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33628184)

  • 1. Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.
    Qi D; Liu H; Sun X; Luo D; Zhu M; Tao T; Gao C; Zhou C; Zhou W; Xiao J
    Front Pharmacol; 2020; 11():621110. PubMed ID: 33628184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss.
    Liu H; Dong Y; Gao Y; Zhao L; Cai C; Qi D; Zhu M; Zhao L; Liu C; Guo F; Xiao J; Huang H
    J Cell Physiol; 2019 Jul; 234(7):11009-11022. PubMed ID: 30548260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhizin Suppresses RANKL-Induced Osteoclastogenesis and Oxidative Stress Through Inhibiting NF-κB and MAPK and Activating AMPK/Nrf2.
    Li Z; Chen C; Zhu X; Li Y; Yu R; Xu W
    Calcif Tissue Int; 2018 Sep; 103(3):324-337. PubMed ID: 29721581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca
    Zeng X; Zhang Y; Wang S; Wang K; Tao L; Zou M; Chen N; Xu J; Liu S; Li X
    Biochem Pharmacol; 2017 Jan; 124():57-68. PubMed ID: 27789216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling.
    Pan B; Zheng L; Fang J; Lin Y; Lai H; Gao J; Pan W; Zhang Y; Ni K; Lou C; He D
    Front Pharmacol; 2021; 12():774709. PubMed ID: 34899338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
    Thummuri D; Naidu VGM; Chaudhari P
    J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss.
    Guo J; Ren R; Guo Z; Sun K; He J; Shao J; Wang X
    Int Immunopharmacol; 2023 Mar; 116():109820. PubMed ID: 36758295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss.
    Liu C; Guan H; Cai C; Li F; Xiao J
    Exp Cell Res; 2017 Mar; 352(2):293-303. PubMed ID: 28209487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
    Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
    J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
    Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
    FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 20. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.